Salud financiera de hoja de balance de Rhinomed

Salud financiera controles de criterios 2/6

Rhinomed tiene un patrimonio de los accionistas total de A$-6.4M y una deuda total de A$5.8M, lo que sitúa su ratio deuda-patrimonio en -90.4%. Sus activos y pasivos totales son A$3.1M y A$9.5M respectivamente.

Información clave

-90.4%

Ratio deuda-patrimonio

AU$5.79m

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	AU$190.41k
Patrimonio	-AU$6.41m
Total pasivo	AU$9.48m
Activos totales	AU$3.08m

Actualizaciones recientes sobre salud financiera

Recent updates

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Nov 10

Is Rhinomed (ASX:RNO) Using Too Much Debt?

Mar 03

Rhinomed (ASX:RNO) Is In A Strong Position To Grow Its Business

Mar 01

Here's Why We're Not Too Worried About Rhinomed's (ASX:RNO) Cash Burn Situation

Jul 09

Here's Why We're Watching Rhinomed's (ASX:RNO) Cash Burn Situation

Mar 01

Key Things To Understand About Rhinomed's (ASX:RNO) CEO Pay Cheque

Jan 25

How Many Rhinomed Limited (ASX:RNO) Shares Did Insiders Buy, In The Last Year?

Dec 20

Análisis de la situación financiera

Pasivos a corto plazo: RNO tiene patrimonio neto negativo. Es una situación más grave que activos a corto plazo que no cubren pasivos a corto plazo.

Pasivo a largo plazo: RNO tiene patrimonio neto negativo. Esta situación es más grave que el hecho de que los activos a corto plazo no cubran los pasivos a largo plazo.

Historial y análisis de deuda-patrimonio

Nivel de deuda: RNO tiene patrimonio negativo, una situación más grave que un alto nivel de endeudamiento.

Reducción de la deuda: RNO tiene patrimonio neto negativo, por lo que no necesitamos comprobar si su deuda se ha reducido con el tiempo.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: RNO tiene suficiente cash runway para 0 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: Se prevé que RNO disponga de suficiente cash runway para 0 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.

Salud financiera de hoja de balance de Rhinomed

Salud financiera controles de criterios 2/6

Información clave

Actualizaciones recientes sobre salud financiera

Is Rhinomed (ASX:RNO) Using Too Much Debt?

Rhinomed (ASX:RNO) Is In A Strong Position To Grow Its Business

Here's Why We're Not Too Worried About Rhinomed's (ASX:RNO) Cash Burn Situation

Here's Why We're Watching Rhinomed's (ASX:RNO) Cash Burn Situation

Rhinomed Limited Auditor Raises 'Going Concern' Doubt

Recent updates

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited Withdraws the Resolution for Re-Election of Ryan McIntyre as a Director

Rhinomed Limited's (ASX:RNO) CEO Will Probably Find It Hard To See A Huge Raise This Year

Rhinomed Limited Announces Retirement of Brent Scrimshaw, Non-Executive Director, Effective from November 17Th, 2023

Full year 2023 earnings released: AU$0.038 loss per share (vs AU$0.02 loss in FY 2022)

Rhinomed Limited, Annual General Meeting, Nov 17, 2023

Full year 2023 earnings released: AU$0.039 loss per share (vs AU$0.02 loss in FY 2022)

New minor risk - Financial data availability

New major risk - Market cap size

Insider recently bought AU$242k worth of stock

Insider recently bought AU$372k worth of stock

Is Rhinomed (ASX:RNO) Using Too Much Debt?

First half 2023 earnings released: AU$0.016 loss per share (vs AU$0.013 loss in 1H 2022)

Less than half of directors are independent

Rhinomed Limited, Annual General Meeting, Nov 18, 2022

Less than half of directors are independent

Rhinomed Limited Announces Rhinoswab Junior Study Confirms New Nasal Swab Is Most Accurate, Comfortable and Easy for Kids

Rhinomed Limited Appoints Lyn Swinburne AO as Non-Executive Director

Full year 2022 earnings released: AU$0.02 loss per share (vs AU$0.034 loss in FY 2021)

Rhinomed (ASX:RNO) Is In A Strong Position To Grow Its Business

Rhinomed Limited Announces the Interim Results in the World First "Rhinoswab for Diagnosis of Respiratory Virus in Children" Trial

CEO, MD & Executive Director exercised options to buy AU$855k worth of stock.

CEO, MD & Executive Director exercised options to buy AU$855k worth of stock.

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Here's Why We're Not Too Worried About Rhinomed's (ASX:RNO) Cash Burn Situation

Non-Executive Director recently bought AU$77k worth of stock

Non-Executive Director recently bought AU$76k worth of stock

Here's Why We're Watching Rhinomed's (ASX:RNO) Cash Burn Situation

First half 2021 earnings released: AU$0.022 loss per share (vs AU$0.034 loss in 1H 2020)

Key Things To Understand About Rhinomed's (ASX:RNO) CEO Pay Cheque

Independent Non-Executive Chairman recently bought AU$180k worth of stock

Insider recently bought AU$435k worth of stock

How Many Rhinomed Limited (ASX:RNO) Shares Did Insiders Buy, In The Last Year?

Rhinomed Limited Detects SARS-CoV-2 in Doherty Inst. RT-PCR Study

Rhinomed Limited Announces Registration of Nasal Swab with Australian Therapeutic Goods Administration

Rhinomed Limited Announces Registration of Its Novel Nasal Swab with the US FDA

Insider recently bought AU$513k worth of stock

Insider recently bought AU$443k worth of stock

Insider recently bought AU$668k worth of stock

Insider recently bought AU$600k worth of stock

Rhinomed Limited Auditor Raises 'Going Concern' Doubt

Full year earnings released - AU$0.044 loss per share

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera